Volume 46, Issue 11 e14160
ORIGINAL ARTICLE

Protective effect of copper II-albumin complex against aflatoxin B1- induced hepatocellular toxicity: The impact of Nrf2, PPAR-γ, and NF-kB in these protective effects

Hend M. Abo-Hiemad

Hend M. Abo-Hiemad

Biochemistry Division, Chemistry Department, Faculty of Science, Al-Azhar University, Cairo, Egypt

Search for more papers by this author
Ahmed Y. Nassar

Ahmed Y. Nassar

Medical Biochemistry Department, Faculty of Medicine, Assiut University, Assiut, Egypt

Search for more papers by this author
Ahmed R. Shatat

Ahmed R. Shatat

Chemistry Department, Faculty of Science, Al-Azhar University, Cairo, Egypt

Search for more papers by this author
Mona A. Mohamed

Mona A. Mohamed

Biochemistry Division, Chemistry Department, Faculty of Science, Al-Azhar University, Cairo, Egypt

Search for more papers by this author
Mahmoud Soliman

Mahmoud Soliman

Department of Pathology and Clinical Pathology, Faculty of Veterinary Medicine, Assiut University, Assiut, Egypt

Search for more papers by this author
Yousef A. Abdelrady

Yousef A. Abdelrady

Faculty of Pharmacy, Assiut University, Assiut, Egypt

Search for more papers by this author
Ahmed M. Sayed

Corresponding Author

Ahmed M. Sayed

Biochemistry Laboratory, Faculty of Science, Chemistry Department, Assiut University, Assiut, Egypt

Correspondence

Ahmed M. Sayed, Biochemistry Laboratory, Chemistry Department, Faculty of Science, Assiut University, Assiut 71515, Egypt.

Email: [email protected]

Contribution: Conceptualization, Data curation, Formal analysis, ​Investigation, Methodology, Writing - original draft, Writing - review & editing

Search for more papers by this author
First published: 25 March 2022
Citations: 8

Abstract

Copper II-Albumin complex (Cu-II-Albumin complex) is a novel therapeutic target that has been used as anti-inflammatory, antioxidant, and anti-gastrointestinal toxicity. In this study, 40 rats were divided into four groups, normal control (NC), aflatoxicosed group (AF) that received Aflatoxin B1 (AFB1) (50 μg/kg of the AFB1 daily for 3 weeks), AFB1-Cu-II-Albumin prophylactic group (AF/CUC-P) that subjected to intermittent treatment between AFB1 and Cu-II-Albumin complex (0.05 g/kg Cu-II-Albumin complex) day after day for 3 weeks and AFB1-Cu-II-albumin treatment group (AF/CUC-T) that received AFB1 for 3 weeks and Cu-II-albumin complex for another 3 weeks. The hepatocellular protective effect of the Cu-II-albumin complex was assessed by evaluating the liver functions markers, hepatic histopathology, reactive oxygen species (ROS) levels (Nitric Oxide (NO) and malondialdehyde (MDA)), apoptotic genes (caspase-3 and tumor necrosis factor receptor 1 [TNF-R1]) expressions, and serological and molecular biomarkers of hepatocellular carcinoma (histamine and Glucose-Regulated Protein 78 [GRP78], respectively). Our finding showed that Cu-II-Albumin Complex administration had restored liver function, oxidative stress levels, enhanced liver tissue recovery, and reduced the expression of the apoptotic genes of the aflatoxicosed rats. In conclusion, the current study results demonstrated the protective effect of Cu-II-albumin complex against AFB1-induced hepatocellular toxicity.

Practical applications

The protective effect of Cu-II-Albumin Complex against AFB1-induced hepatocellular toxicity by assessing oxidative stress, liver biomarkers, inflammation, and histological changes of liver tissues. The protective mechanism of the Cu-II-albumin complex was also investigated. More clinical studies are required to evaluate the potential of using the Cu-II-albumin complex as a therapeutic agent against hepatocellular toxicity.

CONFLICT OF INTEREST

The authors declare that there are no competing interests.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.